Thank You for Meeting Us

We enjoyed meeting you at the American Academy of Neurology meeting

Cognition Therapeutics is currently enrolling participants in Phase 2 clinical trials both in Alzheimer’s Disease and dementia with Lewy bodies. Both studies utilize Cognition’s proprietary lead product candidate, CT1812, an orally delivered, small molecule designed to penetrate the blood-brain barrier and bind selectively to the sigma-2 (σ-2) receptor complex, a key regulator of cellular damage and stress response.
Download
our Vcard

Ongoing Clinical Programs

Indication

Preclinical

Phase 1

Phase 2

Phase 3

SHINE (COG0201) Study

SEQUEL (COG0202) Study

COG0203 in Collaboration with the ACTC

Including Parkinson's disease and DLB

* Subject to discussion with FDA, this clinical development program will begin with a Phase 2 study supported by the Phase 1 AD studies

Novel Approach

The sigma-2 (σ-2) receptor is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. The σ-2 complex is comprised of transmembrane protein 97 (TMEM97), a four-domain transmembrane protein that forms a complex with progesterone receptor membrane component 1 (PGRMC1).

The σ-2 complex is expressed in the CNS, the retina, as well as peripheral organs, including the pancreas, liver and kidney. Within the brain, the σ-2 complex is found in several areas, including the cerebellum, cortex, hippocampus and substantia nigra, and is enriched in neurons as compared to glial cells in the adult brain. In the retina, the σ-2 complex is expressed in several cell types including the RPE cells, photoreceptors and retinal ganglion cells.

We believe that targeting the σ-2 complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases.

Presentations and Publications

AD/PD™ 2022
Analyses from clinical studies of CT1812 in patients with Alzheimer’s disease were presented at AD/PD™ 2022. Click on the poster below to view and download the PDFs.
Publications

Cognition Therapeutics has several publications on the sigma-2 receptor, its role in neurological disorders such as Alzheimer’s disease and results of earlier studies. Select publications are listed below. 

click to open and download

click to open and download

Rishton GM, Look GC, Ni Z-J, et al. Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer’s Disease. ACS Med Chem Lett. 2021 Aug 9;12(9):1389-1395.

Izzo NJ, Yuede CM, LaBarbera KM, et al. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer’s disease modification. Alzheimer’s Dement. 2021 Aug; 17(8):1365-1382

Limegrover CS, LeVine H III, Izzo NJ, et al. Alzheimer’s Protection Effect of A673T Mutation May Be Driven by Lower Aβ Oligomer Binding Affinity. J Neurochem. 2020; 00: 1– 15. doi:10.1111/jnc.15212

Contact Cognition's Clinical Operations Team

Scroll to Top

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Thank you

Someone from the Cognition Therapeutics team
will be in touch with you soon.